C&R Research Inc. (KOSDAQ:359090)

South Korea flag South Korea · Delayed Price · Currency is KRW
823.00
+29.00 (3.65%)
At close: Mar 6, 2026
-22.36%
Market Cap 47.30B
Revenue (ttm) 63.97B
Net Income (ttm) 2.80B
Shares Out 57.47M
EPS (ttm) 49.15
PE Ratio 16.74
Forward PE n/a
Dividend 10.00 (1.22%)
Ex-Dividend Date Dec 29, 2025
Volume 152,390
Average Volume 246,222
Open 763.00
Previous Close 794.00
Day's Range 763.00 - 823.00
52-Week Range 733.00 - 1,216.00
Beta 0.05
RSI 42.00
Earnings Date Feb 11, 2026

About C&R Research

C&R Research Inc. engages in the of clinical development for pharmaceuticals and medical devices. The company’s therapeutic area comprises oncology, cardiovascular, endocrinology, dermatology, central nervous system, ophthalmology, and rare disease.The company was founded in 1997 and is based in Seoul, South Korea. [Read more]

Industry Commercial Physical and Biological Research
Founded 1997
Employees 510
Stock Exchange KOSDAQ
Ticker Symbol 359090
Full Company Profile

Financial Performance

In 2024, C&R Research's revenue was 59.69 billion, an increase of 8.32% compared to the previous year's 55.10 billion. Earnings were 3.84 billion, a decrease of -30.99%.

Financial Statements

News

There is no news available yet.